{"id":"oral-levonadifloxacin-linezolid-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL126","moleculeType":"Small molecule","molecularWeight":"337.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levonadifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Linezolid is an oxazolidinone that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The combination provides synergistic activity against a broad spectrum of gram-positive and gram-negative bacteria, including resistant strains.","oneSentence":"This combination drug inhibits bacterial DNA gyrase (via levonadifloxacin) and bacterial protein synthesis (via linezolid) to kill or stop the growth of susceptible bacteria.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:44.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (specific indications in Phase 3 development not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT03405064","phase":"PHASE3","title":"Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2017-08-25","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":501}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral Levonadifloxacin/Linezolid Tablet","genericName":"Oral Levonadifloxacin/Linezolid Tablet","companyName":"Wockhardt","companyId":"wockhardt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug inhibits bacterial DNA gyrase (via levonadifloxacin) and bacterial protein synthesis (via linezolid) to kill or stop the growth of susceptible bacteria. Used for Bacterial infections (specific indications in Phase 3 development not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}